Sugi Predict

Sugi Predict / Compounds / SCHEMBL1658690

SCHEMBL1658690

SCHEMBL1658690

COC(=O)c1ncc2c(Oc3ccccc3)cccc2c1O

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ EGLN1 Q9GZT9 7/20 0.47
▸ KDM4E B2RXH2 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ CYP1A2 P05177 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ BCL2L1 Q07817 1/20 0.40
▸ MCL1 Q07820 1/20 0.40
▸ EGLN2 Q96KS0 4/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ NUDT1 P36639 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1656353 0.91 ESR1 (0.42) EGLN1CYP1A2CYP2C19MEN1KMT2A
SCHEMBL1657010 0.90 MAOA (0.43) EGLN1
SCHEMBL1656615 0.89 MTNR1B (0.45) KDM4EHSD17B10CYP1A2CYP2C19MEN1
SCHEMBL1656086 0.87 HTT (0.41) EGLN1KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL15547987 0.84 MEN1 (0.43) EGLN1KDM4EHSD17B10CYP1A2CYP2C9
SCHEMBL28055652 0.81 EGLN1 (0.44) EGLN1KDM4EMEN1KMT2A
SCHEMBL31636613 0.81 USP2 (0.48) HSD17B10CYP1A2CYP2C9CYP2C19SMN1; SMN2
SCHEMBL1656047 0.81 EGLN1 (0.48) EGLN1KDM4EHSD17B10CYP1A2CYP2C9
SCHEMBL1219109 0.81 EGLN1 (0.65) EGLN1
SCHEMBL3779838 0.80 EGLN1 (0.45) EGLN1BCL2L1MCL1EGLN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3219706-A1 PROCESS FOR MAKING ISOQUINOLINE COMPOUNDS Fibrogen, Inc. (US) 2017-09-20 — — EP disclosed
US-9708269-B2 Process for making isoquinoline compounds FIBROGEN, INC. (US) 2017-07-18 — — US disclosed
US-9708269-B2 Process for making isoquinoline compounds FIBROGEN, INC. (US) 2017-07-18 — — US disclosed
EP-2872487-B1 PROCESS FOR MAKING ISOQUINOLINE COMPOUNDS FIBROGEN INC (US) 2017-04-26 — — EP disclosed
US-20160194285-A1 PROCESS FOR MAKING ISOQUINOLINE COMPOUNDS FIBROGEN, INC. 2016-07-07 — — US disclosed
US-20160194285-A1 PROCESS FOR MAKING ISOQUINOLINE COMPOUNDS FIBROGEN, INC. 2016-07-07 — — US disclosed
US-9340511-B2 Process for making isoquinoline compounds FIBROGEN, INC. (US) 2016-05-17 — — US disclosed
US-9340511-B2 Process for making isoquinoline compounds FIBROGEN, INC. (US) 2016-05-17 — — US disclosed
US-20160009653-A1 CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF FIBROGEN, INC. 2016-01-14 — — US disclosed
US-9174976-B2 Cyanoisoquinoline compounds and methods of use thereof FIBROGEN, INC. (US) 2015-11-03 — — US disclosed
US-20150031696-A1 CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF FIBROGEN, INC. (US) 2015-01-29 — — US disclosed
US-8759373-B2 Cyanoisoquinoline compounds and methods of use thereof FIBROGEN, INC. (US) 2014-06-24 — — US disclosed
EP-2476669-A1 Cyanoisoquinoline compounds and methods of use thereof Fibrogen, Inc. (US) 2012-07-18 — — EP disclosed
US-20120178755-A1 CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF FIBROGEN, INC. 2012-07-12 — — US disclosed
EP-2044028-B1 CYANOISOQUINOLINE COMPOUNDS THAT STABILIZE HYPOXIA INDUCIBLE FACTOR (HIF) FIBROGEN INC (US) 2012-05-16 — — EP disclosed
US-20110212959-A1 Cyanoisoquinoline Compounds and Methods of Use Thereof FIBROGEN, INC. 2011-09-01 — — US disclosed
US-7928120-B2 Cyanoisoquinoline compounds and methods of use thereof FIBROGEN, INC. (US) 2011-04-19 — — US disclosed
EP-2044028-A2 CYANOISOQUINOLINE COMPOUNDS THAT STABILIZE HYPOXIA INDUCIBLE FACTOR (HIF) FIBROGEN, INC. (US) 2009-04-08 — — EP disclosed
US-20070298104-A1 CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF FIBROGEN, INC. 2007-12-27 — — US disclosed
WO-2007090068-A2 CYANOISOQUINOLINE COMPOUNDS THAT STABILIZE HYPOXIA INDUCIBLE FACTOR (HIF) FIBROGEN, INC. (US) 2007-08-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160194285-A1 PROCESS FOR MAKING ISOQUINOLINE COMPOUNDS HIF1AN, HIF1A, EGLN3 EGLN1 5/4885KDM4E 613/4885HSD17B10 646/4885
US-20160009653-A1 CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF HIF1AN, HIF1A, EGLN3 EGLN1 5/4885KDM4E 892/4885HSD17B10 1620/4885
US-20070298104-A1 CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF HIF1AN, HIF1A, EGLN3 EGLN1 7/4885KDM4E 987/4885HSD17B10 2457/4885
US-20120178755-A1 CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF HIF1AN, HIF1A, EGLN3 EGLN1 7/4885KDM4E 987/4885HSD17B10 2457/4885
US-20150031696-A1 CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF HIF1AN, HIF1A, EGLN3 EGLN1 7/4885KDM4E 987/4885HSD17B10 2457/4885
US-20110212959-A1 Cyanoisoquinoline Compounds and Methods of Use Thereof HIF1AN, HIF1A, EGLN3 EGLN1 7/4885KDM4E 987/4885HSD17B10 2457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.